Brochopro 7.5 mg/ml solution 30 ml

Tradename:

Bronchopro (Bronchopro)

Compound:

Each 1 ml of solution contains:

Ambroxol hydrochloride 7.5 mg

Auxiliary components:

Methyl parahydroxybenzoate, sodium chloride, propylene glycol, purified water.

Properties:

Mucolytic and expectorant, is an active N-demethylated metabolite of bromhexine. It has a secretomotor, secretolytic and expectorant action. Stimulates the serous cells of the bronchial mucosa, increases the motor activity of the ciliated epithelium by acting on type 2 pneumocytes in the alveoli and Clara cells in the bronchioles, enhances the formation of endogenous surfactant – a surfactant that ensures the sliding of bronchial secretions in the lumen of the respiratory tract.

Ambroxol increases the proportion of the serous component in the bronchial secretion, improving its structure and helping to reduce the viscosity and thin the sputum; as a result of this, mucociliary transport improves and the removal of sputum from the bronchial tree is facilitated.

When taking Ambroxol orally, the effect, on average, occurs after 30 minutes and lasts 6-12 hours, depending on the single dose.

Indications:

Diseases of the respiratory tract, accompanied by the release of viscous sputum and difficulty in expectoration of sputum: acute and chronic bronchitis; pneumonia; bronchial asthma; bronchiectasis; COPD

Dosage and administration:

The duration of treatment is determined by the doctor individually and depends on the severity of the disease. If it is necessary to use the drug for more than 4-5 days, a doctor’s consultation is required.

For oral administration, the dose is set individually and depends on the age of the patient and the dosage form used.

Adults take 4 ml 3 times a day.

Children under 2 years of age take 1 ml 2 times a day.

Children from 2-6 years old take 1 ml 3 times a day.

Children over 6 years old take 2 ml 2-3 times a day.

Contraindications:

Hypersensitivity to ambroxol or auxiliary components of drugs; I trimester of pregnancy; lactation period (breastfeeding).

Precautionary measures:

Ambroxol should not be taken concomitantly with antitussive drugs that can inhibit the cough reflex, such as codeine, because. this can make it difficult to remove liquefied sputum from the bronchi.

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking Ambroxol are not recommended to perform breathing exercises due to difficulty in sputum discharge. In critically ill patients, thin sputum should be aspirated.

Ambroxol should not be taken at bedtime.

In patients with bronchial asthma, ambroxol may increase cough.

Side effects:

Allergic reactions: rarely – skin rash, urticaria, exanthema, swelling of the face, shortness of breath, itching, fever; frequency unknown – anaphylactic reactions, including anaphylactic shock, angioedema, pruritus, allergic contact dermatitis.

From the digestive system: often – nausea; infrequently – vomiting, diarrhea, dyspepsia, abdominal pain.

From the nervous system: often – dysgeusia.

From the skin and subcutaneous tissues: very rarely – toxic epidermal necrolysis (Lyell’s syndrome), Stevens-Johnson syndrome; frequency unknown – acute generalized eczematous pustulosis.

From the respiratory system: often – decreased sensitivity in the oral cavity or pharynx; rarely – dryness of the mucous membrane of the respiratory tract, rhinorrhea; in isolated cases – dryness of the mucous membrane of the pharynx.

Storage method:

Store at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains a 30 ml bottle, paper instructions.